Key clinical point : Presence of acute kidney injury (AKI) may have an adverse impact on the clinical course of patients with acute myeloid leukemia (AML) treated with induction chemotherapy.
Major finding : 72 (18%) AML patients had AKI during induction chemotherapy. AML patients with AKI vs without AKI had more days with fever (7 vs. 5, P = .028) and require treatment intensive care unit more often (45.8% vs. 10.6%, P less than .001). AML patients with AKI also had a significantly lower complete remission rate following induction chemotherapy and shorter median overall survival.
Study details : Retrospective analysis of data from 401 patients with AML undergoing induction chemotherapy between 2007 and 2019.
Disclosures: Open access funding was enabled and organized by Projekt DEAL. The authors declared no conflicts of interest.
Source: Ballo O et al. Ann Hematol. 2021 March 11. doi: 10.1007/s00277-021-04482-3 .